Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60p -4.90% 11.65p 11.30p 12.00p 12.25p 11.65p 12.25p 124,214 10:24:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.4 -3.1 - 10.64

Synairgen Share Discussion Threads

Showing 701 to 723 of 725 messages
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
11/1/2018
15:34
Hi PDT - well i thought not too but i'm not sure either - PXS got another 15m$ from Boehringer for a diabetic retinopathy 2a trial (see below) I'm only mentioning this because Boehringer is on the hook for coughing up 100's of million dollars to PXS if the several trials they have with them go well .I'm in PXS because I expect them to bid for PXS at some point later this year/early next year - an opportunistic bid would save them a lot of money - so then if the loxl trials go well we are partnered with Boehringer who will surely buy out our 17% too. But thats just one scenario ... http://www.pharmaxis.com.au/assets/Documents/pdf/02017/ASX/2017-11-13-PXS-AGM-Presentation-by-CEO.pdf Dosing of the first patient in Boehringer Ingelheim’s Phase 2a clinical trial in patients with diabetic retinopathy triggered the payment. It is the second disease targeted by the drug developed by Pharmaxis, which is being used in a Phase 2a clinical trial for the chronic liver disease NASH (non‐alcoholic steatohepatitis). The studies into NASH and diabetic retinopathy are due to report in the second half of 2018. Today’s payment further strengthens the Pharmaxis balance sheet, which held $39 million in cash at the end of September 2017. Gary Phillips, chief executive officer, said: “This milestone payment marks the expansion of the Boehringer Ingelheim development plan for BI 1467335 into two diseases. “All the potential development milestones in the $625 million deal would be payable to Pharmaxis should both indications be approved. “Both development plans attract the same total development payments through to approval, with the second indication milestone payments weighted more towards approval. “The next milestones from BI are payable if they choose to commence phase 3 trials, at which time the two indications would attract €62 million [circa $94 million] in milestones.”
ohisay
11/1/2018
14:17
There seems to be good buying activity here today. I did see Pharmaxis had a news release today about receiving a milestone payment but I don't think its related to their Fibrosis deal with SNG.
pdt
02/1/2018
23:44
https://www.thesun.co.uk/news/5255776/aussie-flu-outbreak-sees-uk-cases-rocket-by-48-in-just-one-week/
ohisay
29/12/2017
20:12
I guess I am a bit worried about patent expiry. It's taken 12 years to get to this stage and phase II hasn't started yet. I believe expiry is 2030. Having said that I have continued to buy here.
pdt
29/12/2017
17:43
Good post again .At 11p buy you can make money here i've been doing it for 6 years.
ohisay
29/12/2017
17:10
SNG appears to be an invisible gem to the majority of Investors.. We have a unique British Company based in Southampton General Hospital using its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease.Prof Stephen Holgate, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton is a Non Exec Director of SN SNG will very soon have £5m from Pharmaxis, plus my guess is approx £2.0 million in its cash reserves.. and importantly NO DEBT... Approx 64% of the shares are held by 5 shareholders with Woodford Investment Managers holding over 23% of the SNG share capital..and approx 91 Million shares in existance.. With a dynamic management led by CEO Richard Marsden, who I calculate pulled off a unique and lucrative deal of SNG investing my guess is £3m in LOXL2 and 2 years later has converted this investment into a £5m Paycheck for shareholders and critcally important a 17% stake in the COMPLETE Pharmaxis LOXL Programme... Phase 1 Trials by Pharmaxis in the LOXL Programme are commencing with the following comment by its CEO “Ongoing discussions with multinational Pharma companies suggest that there is a significant opportunity for an oral once a day LOXL2 inhibitor in a number of fibrotic diseases with a high unmet need.  With COPD news by SNG expected sometime after Q1 2018 and regular updates by Pharmaxis on its LOXL Programme during Q1 and Q2 2018... The potential risk reward for Synairgen shareholders does offer a very signifcant reward opportunity.. for those willing to complete the journey to see both these key Programmes end points.. A very successful and prosperous New Year to current and future SNG Investors.
rosejs2
29/12/2017
09:38
Bought another capful 10k today - COPD news due and PXS loxl trials kicking off very shortly.
ohisay
20/12/2017
05:08
Good post - I agree with all of that.Having been here for the most part over 6 years the price can move up or down on very little volume - its been a very successful share for me to accumulate when its been oversold (a few months ago I bought around 50k at 7.5p for example some of which I sold last week at 18p) I'd also be surprised if the directors weren't thinking about topping up at these levels - cant think they have any more information to hand that isn't in the public domain now. Of course there's going to be little substantive news on the two trials until end Q2/into Q3 but the downside of holding until then given the large cash position is minimal - and these guys really don't fritter cash away. And given all this it wouldn'r surprise me if it wasn't tipped in the media too. PS I do wish SNG would publish broker notes like PXS does (expect some more of those on the PXS website shortly - following the SNG deal ) http://www.pharmaxis.com.au/investor-centre/analyst-coverage/
ohisay
19/12/2017
19:18
ohisay ... I do agree with your sentiments.. Here we have a company with NO debt, £5m to come from Pharmaxis, 17% of future revenues from LOXL2 Developments (these could be huge if the Phase 1 trials meet expectations and the right partners found)... Approx £2m in current cash... Alongside progression of SNG001 into COPD, What is there not to like.. If you look at the Major shareholders 5 of which including Woodford Investment Management own approx 64% of the issued equity...only 91.36 million shares... Both areas of development LOXL2 and COPD are if successfull worth Billions to major Pharma Partners... whilst the 'IF' is speculative.. the quality of both Management and Scientific Expertise in both Pharmaxis and SNG is second to none.. Why is the share price falling ? my view for what it is worth is that SNG shares are quite illiquid small sales or purchases can move the price one way or the other .. and currently some small sells are driving the price down.. It may on the other hand be a tree shaking exercise by the market makers who require stock to meet their obligations.. and hitting individual stop losses may be the only way to obtain stock... but that is just my speculation.. 2018 will be a very exciting year for SNG for both LOXL2 and progress on COPD ... If SNG management can supply regular updates on progress, the market should become more aware of the real potential of SNG and its revenue streams. The market should then respond positively in raising SNG shares substantially above its current lowly Price..
rosejs2
19/12/2017
18:16
Isn't it just wonderful that it gets marked down every day - another 1p down and I will buy the farm.
ohisay
18/12/2017
10:39
Averaged down a bit today, I like to look of SNG.. good interview , thanks for posting
urigem
17/12/2017
13:30
Has it occured to others why Pharmaxis did not bid for SNG as a means of achieving 100% ownership of the LOXL2 Programme ? or was there an attempt to do so before signing the latest agreement with SNG to share revenues... Might the large shareholders have been (quite rightly ) demanding a price substantially in excess of the current share price ? Might Pharmaxis be a future bidder of SNG if all goes well with its Phase 1 / Partnership agreements... And be able to add SNG's COPD potential blockbuster to its portfolio ?
rosejs2
17/12/2017
12:07
A more comprehensive strategy update from Synairgen would be welcome. They've done an admirable job of handling the AZ disappointment and bringing in cash with this new Pharmaxis deal. On the other hand, it's hard to see where things go from here. We have: (1) The interferon-beta, somewhat tarnished after its return from AZ, which will now enter P1/2a in COPD. It's likely to absorb most of the company's resources but it's hard to see a licence or P3 before the 2020s. (2) A 17 per cent stake in the LOXL2 programme which is just entering P1 and aiming for a licence deal next year. That could bring in further cash but is unlikely to be transformative in the short or medium-term. Synairgen seems high-quality and commercially-minded but it's regressed to being an early-stage company. It'd be good to know how they ultimately plan to deliver value and what further capital they expect to need in the process of getting there.
mirako
15/12/2017
08:21
Another 20k for me - EV of only £5m/£6m is much too low for the potential upside .
ohisay
14/12/2017
17:55
Huge trade...but What does non protected portfolio single protected transaction mean??
babbler
14/12/2017
15:49
Patients. Damn auto correct.
babbler
14/12/2017
15:48
I hear they plan to use blockchain to help asma patience :D
babbler
14/12/2017
15:25
ohisay... Spot on...Great Interview with Richard Marsden on ProactiveInvestors Many thanks
rosejs2
14/12/2017
15:07
I think thats what you were trying to bring up https://www.youtube.com/watch?v=-6NW_mqd7Cs
ohisay
14/12/2017
15:07
Will probably close red at this rate. They ought to rename the company SynAirCoin, then we'd be +5000%
boffster
14/12/2017
14:50
[...] Synairgen chief delighted with amended fibrosis collaboration deal Share 11:34 14 Dec 2017
rosejs2
14/12/2017
13:51
Long term hold it is :D
babbler
14/12/2017
12:08
Great that funding uncertainty is resolved. Expect to hear news on the COPD trial soon. Nice to have a decent share of the upside across Fibrosis range with no ongoing cost. 2018 will be a very interesting year. If partners in both areas are announced over the next 12 months where will the share price be? I have added on this morning's news :)
pdt
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180117 03:31:35